Abstract
Family C of G-protein coupled receptors (GPCRs) from humans is constituted by eight metabotropic glutamate (mGlu1-8) receptors, two heterodimeric -aminobutyric acidB (GABAB) receptors, a calcium-sensing receptor (CaR), three taste (T1R) receptors, a promiscuous L- α-amino acid receptor (GPRC6A), and five orphan receptors. Aside from the orphan receptors, the family C GPCRs are characterised by a large amino-terminal domain, which bind the endogenous orthosteric agonists. Recently, a number of allosteric modulators binding to the seven transmembrane domains of the receptors have also been reported. Family C GPCRs regulate a number of important physiological functions and are thus intensively pursued as drug targets. So far, two drugs acting at family C receptors (the GABAB agonist baclofen and the positive allosteric CaR modulator cinacalcet) have been marketed. Cinacalcet is the first allosteric GPCR modulator to enter the market, which demonstrates that the therapeutic principle of allosteric modulation can also be extended to this important drug target class. In this review we outline the structure and function of family C GPCRs with particular focus on the ligand binding sites, and we present the most important pharmacological agents and the therapeutic prospects of the receptors.
Keywords: Metabotropic glutamate receptor, calcium-sensing receptor, γ-aminobutyric acidB receptor, GPRC6A
Current Drug Targets
Title: Structure, Pharmacology and Therapeutic Prospects of Family C G-Protein Coupled Receptors
Volume: 8 Issue: 1
Author(s): Hans Brauner-Osborne, Petrine Wellendorph and Anders A. Jensen
Affiliation:
Keywords: Metabotropic glutamate receptor, calcium-sensing receptor, γ-aminobutyric acidB receptor, GPRC6A
Abstract: Family C of G-protein coupled receptors (GPCRs) from humans is constituted by eight metabotropic glutamate (mGlu1-8) receptors, two heterodimeric -aminobutyric acidB (GABAB) receptors, a calcium-sensing receptor (CaR), three taste (T1R) receptors, a promiscuous L- α-amino acid receptor (GPRC6A), and five orphan receptors. Aside from the orphan receptors, the family C GPCRs are characterised by a large amino-terminal domain, which bind the endogenous orthosteric agonists. Recently, a number of allosteric modulators binding to the seven transmembrane domains of the receptors have also been reported. Family C GPCRs regulate a number of important physiological functions and are thus intensively pursued as drug targets. So far, two drugs acting at family C receptors (the GABAB agonist baclofen and the positive allosteric CaR modulator cinacalcet) have been marketed. Cinacalcet is the first allosteric GPCR modulator to enter the market, which demonstrates that the therapeutic principle of allosteric modulation can also be extended to this important drug target class. In this review we outline the structure and function of family C GPCRs with particular focus on the ligand binding sites, and we present the most important pharmacological agents and the therapeutic prospects of the receptors.
Export Options
About this article
Cite this article as:
Brauner-Osborne Hans, Wellendorph Petrine and Jensen A. Anders, Structure, Pharmacology and Therapeutic Prospects of Family C G-Protein Coupled Receptors, Current Drug Targets 2007; 8 (1) . https://dx.doi.org/10.2174/138945007779315614
DOI https://dx.doi.org/10.2174/138945007779315614 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Bone Effects of Glitazones and Other Anti-Diabetic Drugs
Current Drug Safety Circulating Tumor Cells: A New Window for Diagnosis and Evaluation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety Fibroblast Growth Factor-2, Bone Homeostasis and Fracture Repair
Current Pharmaceutical Design Pathophysiology and Treatment of Nonfamilial Hyperparathyroidism
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections :
Recent Patents on Biomarkers Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design The Oxygen Therapy
Current Medicinal Chemistry TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Lactoferrin in Bone Tissue Regeneration
Current Medicinal Chemistry Dendritic Cells: A New Player in Osteoimmunology
Current Molecular Medicine Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Disorders of Mineral Metabolism in the Newborn
Current Pediatric Reviews Monitoring Molecular, Functional and Morphologic Aspects of Bone Metastases Using Non-Invasive Imaging
Current Pharmaceutical Biotechnology CRH Receptor Signalling: Potential Roles in Pathophysiology
Current Molecular Pharmacology Further Vitamin D Analogs
Current Vascular Pharmacology Genetic Alterations in Medullary Thyroid Cancer: Diagnostic and Prognostic Markers
Current Genomics